Xinfeng F. Chen

1 Jianshe East Road
Zhengzhou, 450052, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications

Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions.

Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions.

Journal: Molecular immunology
Published: December 28, 2025

H2AFY2 suppresses exhaustion and enhances antitumor activity of CAR-T cells through transcriptional and epigenetic modifications.

H2AFY2 suppresses exhaustion and enhances antitumor activity of CAR-T cells through transcriptional and epigenetic modifications.

Journal: Cancer immunology research
Published: October 24, 2025

In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy.

In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy.

Journal: Human vaccines & immunotherapeutics
Published: September 11, 2025

Allogeneic CAR-T cells for cancer immunotherapy.

Allogeneic CAR-T cells for cancer immunotherapy.

Journal: Immunotherapy
Published: October 08, 2024

Pseudoprogression in CAR-T cell therapy for solid tumor: Case report.

Pseudoprogression in CAR-T cell therapy for solid tumor: Case report.

Journal: Frontiers in immunology
Published: September 30, 2024

Advances in targeting tumor microenvironment for immunotherapy.

Advances in targeting tumor microenvironment for immunotherapy.

Journal: Frontiers in immunology
Published: July 30, 2024

Comparison of Mutant Prevention Concentrations of Fluoroquinolones Against ESBL-Positive and ESBL-Negative Klebsiella pneumoniae Isolates from Orthopedic Patients.

Comparison of Mutant Prevention Concentrations of Fluoroquinolones Against ESBL-Positive and ESBL-Negative Klebsiella pneumoniae Isolates from Orthopedic Patients.

Journal: Microbial drug resistance (Larchmont, N.Y.)
Published: July 17, 2024

PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors.

PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: February 13, 2024

Peripheral Blood-Derived PD-1/CD28-CD19 CAR-Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors.

Peripheral Blood-Derived PD-1/CD28-CD19 CAR-Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors.

Journal: Cancer immunology research
Published: January 11, 2024

Correction: IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma.

Correction: IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma.

Journal: Oncogene
Published: September 18, 2023

Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies.

Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies.

Journal: Cancer immunology, immunotherapy : CII
Published: July 18, 2023

Correction: miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma.

Correction: miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma.

Journal: Oncotarget
Published: May 19, 2023
Showing 1-12 of 69

Last Updated: 09/26/2026